Related Experiment Video
Updated: Apr 30, 2026

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
Published on: August 16, 2020
Retrospection dropout bare-bones particle swarm optimization for feature-based brain tumor classification in MRI
Wenting Chen1,2, Tiezhu Shi3, Jia Guo4,5,6
1School of Biomedical Engineering, State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, Hainan University, Haikou, China.
None:
Brain cancer remains a critical global health challenge, where early and accurate diagnosis remains a critical challenge in clinical practice. Current supervised learning methods for tumor classification face substantial limitations due to their dependence on large labeled datasets requiring costly pixel-level annotations, susceptibility to annotation biases, and poor generalization across diverse populations. To address these challenges, this paper proposes Retrospection Dropout Bare-Bones Particle Swarm Optimization (RDBPSO), a novel feature-based classification framework that requires only image-level class labels without the need for pixel-level annotation or manual segmentation masks. The proposed RDBPSO introduces two key innovations: (1) a retrospection mechanism that maintains dual-layer memory structures (optimal and sub-optimal solutions) to enhance particle diversity and prevent premature convergence, and (2) a dropout strategy that reduces computational complexity through intelligent particle interaction sampling. Extensive experiments on an 800-image brain MRI dataset demonstrate RDBPSO's superior performance. The proposed method achieves 90.12% classification accuracy, outperforming standard PSO (89.25%), GMM (77.50%), and K-means (72.75%), while delivering robust clustering quality with an ARI of 0.6436, NMI of 0.5511, and FMI of 0.8229. These results demonstrate the algorithmic promise of RDBPSO as an annotation-efficient framework for brain tumor MRI classification, warranting further investigation on more diverse and clinically representative datasets.

